Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0624 | -31.2 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
| 4 | -0.0624 | -31.2 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
| 12 | -1.0424 | -88.3389830508 | 1.18 | 1.22 | 0.121 | 398938 | 0.49392249 | CS |
| 26 | -0.7624 | -84.7111111111 | 0.9 | 3.39 | 0.121 | 1787506 | 1.26578517 | CS |
| 52 | -4.0024 | -96.6763285024 | 4.14 | 7.6699 | 0.121 | 1599317 | 2.23200941 | CS |
| 156 | -77.6624 | -99.8231362468 | 77.8 | 89.566 | 0.121 | 810790 | 6.93806709 | CS |
| 260 | -103.4624 | -99.8671814672 | 103.6 | 486.8 | 0.121 | 751842 | 58.96792117 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
